The idea of adjusting freezing conditions to while maximal survival of dendritic cells was attained at cooling rates of the order of 1°C/min, survival fell sharply at higher cooling rates and was negligible at 70°C/min. This suggested that pancreatic islets could be cooled under conditions that would allow survival of the beta-cells yet would kill dendritic cells. When tested by transplantation, this method did indeed extend graft survival: but, in order for the islets to survive high cooling rates, they had to be placed into tissue culture both before and after freezing. It; The immunomodulatory effect of freezing was, therefore, confounded by the period in culture, which had previously been shown to be effective by itself in prolonging graft survival in both pancreatic islets and thyroid tissue.9, 19 Ingham et al,zo investigated the use of freezing to achieve immunodulation of skin. The immunogene city of skin was assessed by the immunostimulatory capacity of isolated epidermal cells in primary one way epidermal cell/lymphocyte reaction tests. Meta bolically active Langerhans cells must be present in the epidermal cell suspension for a response to be elicited. Ingham et al. found that skin cooled at 30°C/min in 15 % dimethyl sulphoxide retained significant viability while reducing immunogenicity, presumably through incapacitation of Langerhans cells. After freezing, there was little apparent fall in Langerhans cell numbers (detected by (3-g1ucuroni dase staining) in epidermal sheets; but there was no indication that they were metabolically active, and epidermal cell fractions isolated from frozen skin contained far fewer Langerhans cells than cell fractions from unfrozen skin. It was concluded, therefore, that by choosing appropriate freezing conditions both preservation of skin and reduction in immunogenicity could indeed be achieved. Such results with skin, along with those with pancreatic islets and thyroid tissue, thus encouraged the view that immunomodulation through removal of dendri tic cells was indeed possible and desirable as a means to facilitate prolonged graft survival.
Storage of Corneas fo r Transplantation
There are three main approaches to storage of corneas for transplantation, viz. organ culture at approximately normothermia, hypothermic storage at 0-4°C, and cryopreservation,zl The latter should provide a virtually unlimited storage time, but current methods are too unreliable to be applied successfully by eye banks. Storage at 4°C is technically straightforward and is currently the method of choice in the United States, but even with the latest preservation media storage times are 229 limited to less than 2 weeks and many eye banks will not store corneas at 4°C beyond 7-10 days. Organ culture, on the other hand, allows up to 4 weeks of storage. This method is used widely among the major European eye banks, and has been used in the Corneal Transplant Service (CTS) Eye Bank in Bristol since 1986.
In Bristol, corneas are stored at 34°C in Eagle's minimum essential medium (MEM) with Hepes buffer containing 2% fetal calf serum, L-glutamine, 25 mmolll sodium bicarbonate and antibiotics. Two days before transplantation, the corneal endothelium is examined for any defects by light microscopy and endothelial cell density is estimated. 21 In the 8 years since it opened, the Bristol eye bank has supplied corneas for more than 11 000 grafts in 200 hospitals throughout the United Kingdom and graft survival is 89% at 1 year.
Effects of Organ Culture on Corneal Langerhans Cells
The effect of culture on the immunogenicity of thyroid tissue and pancreatic islets has already been mentioned. Holland et al. 22 showed that after more than 1 week in organ culture, Langerhans cells could not be detected by ATPase staining on most human corneas. Loss of Langerhans cells during organ culture has also been reported by Pels et al. 23 The corneal epithelium comprises five or six layers of cells, but epithelium is shed during organ culture, leaving only two or three layers of cells. The loss of Langerhans cells is thought to be mainly a conse quence of these epithelial changes.
Does Organ Culture Reduce Corneal Immunogeni city?
Despite the apparent absence of Langerhans cells in organ-cultured corneas and the reduced amount of epithelium, immunological rejection is still the most common cause of graft failure. According to the Corneal Transplant Follow-Up Study (CTFS)? 4 which monitored the outcome of 2311 grafts in the United Kingdom, the overall graft survival rate at 1 year was 89%, and rejection-free survival was 87%. Of the 207 grafts that failed, 69 (33 % ) were the result of immunological rejection. The great majority of grafts in the CTFS used organ-cultured corneas, but the 8% of grafts carried out with corneas stored for short periods at 4°C (either as whole eyes or in M-K medium) were not associated with an increased risk of failure or rejection. Increased risk of rejection was associated with vascularisation of the recipient cornea and previously failed grafts. A direct comparison of grafts using corneas stored at 4°C or by organ culture also failed to show any differences in rejection rates,z5
The supposition that organ culture reduces immunogenicity of human corneas through loss of Langerhans cells appears, therefore, to be somewhat tenuous -perhaps purely because a central 7.5 mm corneal button is unlikely to possess many Langer hans cells even in a 'fresh', unstored cornea.
CORNEAL LANGERHANS CELLS AND GRAFT REJECTION
Given their low numbers and typical absence from the central cornea, the extent to which donor Langerhans cells act as professional antigen present ing cells (APC) in stimulating allograft rejection responses in human corneal transplantation has yet to be resolved. Chemical stimulation with dinitrofluorobenzene (DNFB) was used by Rubsamen et al. 26 to increase numbers of Langerhans cells in murine corneas before heterotopic transplantation. Donor corneas that contained high numbers of Langerhans cells were capable of sensitising recipients and subsequent skin grafts were rejected much more rapidly than in recipients that had received corneal grafts without Langerhans cells.
On the other hand, Gebhardt27 questioned whether an orthotopic corneal graft carried suffi cient APC to stimulate a host response. Class II positive cells derived from rat donor spleens were injected into either corneal stroma or the peritoneal cavity of recipient rats. Subsequent skin grafts in the latter group were rejected more rapidly, whereas injection of even 2 X 107 class II bearing cells into stroma failed to elicit an accelerated rejection response.
Katami28 studied corneal rejection phenomena in rats in an extensive series of experiments. Evidence that Langei-hans cells could play an important role came from the following observations. First, grafts larger than 3 mm in diameter were rejected whereas grafts less than 2 mm in diameter were not. Second, grafts with few Langerhans cells (taken from the centre of a donor's cornea) but grafted to a recipient's peripheral cornea tended to show chronic rejection; but grafts with many Langerhans cells (from a donor's peripheral cornea) grafted to a recipient's central cornea tended to be acutely rejected. Finally, purported depletion of APC by hypothermic storage for 1 week or by UV-B irradiation prevented acute rejection ..
Removal of donor epithelium from human corneas has been suggested as a way of lowering the risk of graft rejection either by reducing the overall antigenic load (the epithelium comprises 90% of the cells in a cornea) or, more specifically, by removing the donor Langerhans cells. A prospec tive, randomised study showed that patients who received corneas devoid of donor epithelium had a far lower incidence of rejection than those who were W.1. ARMITAGE grafted with corneas with an intact epithelium (8% vs 30%)?9
Reports that smaller corneal grafts in humans survived better than larger grafts have been put forward as evidence for involvement of Langerhans cells in allograft rejection?O Multifactorial studies that simultaneously analysed donor, operative and recipient factors could not confirm such a clear-cut effect of graft size,3l or found that grafts both smaller than 7 mm or larger than 8 mm showed poorer survival.32
What is the Mechanism of Human Corneal Allograft Rejection?
Grafts in rats or mice can be manipulated such that the donor button can contain various numbers of Langerhans cells. It appears from such studies that acute rejection is associated with the presence in the graft of donor Langerhans cells and that strategies to reduce or eliminate donor Langerhans cells prolong graft survival. The evidence for such a relationship in human corneal grafts is circumstantial. In the first place, it is unlikely that human corneal buttons carry many donor Langerhans cells because of the restricted distribution of these cells to the periphery of the cornea. Although complete removal of the epithelium appears to reduce the incidence of rejection episodes, it is not necessarily the case that large grafts are more susceptible to failure than small grafts. Moreover, organ culture of human corneas not only removes Langerhans cells but also reduces the amount of epithelium, yet there is no firm evidence of reduced risk of rejection when such corneas are transplanted.
There would appear to be three options for inducing an allograft reaction in the presumed absence of donor Langerhans cells: first, that donor stromal dendritic cells act as APC; second, that donor epithelial or endothelial cells act as APC; and, finally, that host APC activate recipient T-cell responses via the indirect pathway. All cell types in the human cornea express class I MHC antigen, but class II antigen is normally expressed only by the Langerhans cells and by a few dendritic cells in the stroma? Unfortunately, little seems to be known of the fate of the stromal dendritic cells either during storage or following transplantation. As fa� as antigen presentation by other corneal cells is concerned, it has been shown in a number of studies that corneal epithelium, endothelium and stromal keratocytes can express class II antigen when stimulated in vitro with gamma-interferon and in vivo during allograft rejection episodes?3-35 But expression of class II antigen per se is insufficient for T-cell activation, which also requires the presence of co-stimulatory factors such as interleukin-1 (IL-1). Indeed, the absence of such factors could result in down-regulation of the T-cell response?6 IL-l production by corneal epithelium and endothelium has, however, been reported?7 In addition, corneal endothelium induced to express class II antigen can function as stimulator cells in a mixed leucocyte reaction,3R and presentation of viral antigen by corneal epithelium in the absence of Langerhans cells has also been postulated? 9 If donor APC are either absent or present in insufficient numbers to stimulate host T-cell responses, then it is possible that host Langerhans cells could initiate an allograft rejection response via the indirect pathway. Pepose et al. 3 5 found Langer hans cells in the central region of rejecting corneas, and they concluded that these cells were of host, not donor, origin because of their failure to detect class II positive cells in the centre of control corneas. There is some, albeit preliminary, evidence to support the indirect pathway of T-cell activation in corneal transplantation from the results of class II MHC matching in the Corneal Transplant Follow-Up Study.24 Class II matching should reduce the like lihood of T-cell activation via the direct pathway, whereas the indirect pathway should be unaffected or even enhanced by class II matching. 40 The CTFS data showed a beneficial effect of class I matching but increased risk of rejection with class II matching. Confirmation of this finding WOUld, therefore, lend support to the contention that recipient APC may be involved in the activation of allogeneic T-cell responses in corneal transplantation.
In summary, Langerhans cells are lost from corneas during storage by organ culture; but, unlike other tissues such as thyroid, skin and pancreatic islets, this depletion of APC does not appear to reduce the likelihood of graft rejection, at least in humans. Corneal grafts in rodents, where the population of Langerhans cells can be artificially elevated in the donor cornea before grafting, have shown that donor Langerhans cells can play a role in initiating allograft rejection of cornea. On the other hand, the typical scarcity of Langerhans cells in the central cornea suggests that human corneal grafts are likely, especially following storage by organ culture, to carry few, if any, Langerhans cells. The extent to which donor Langerhans cells are involved in rejection of human corneas is, therefore, open to question.
